Literature DB >> 17984679

Protein aggregation mechanisms in synucleinopathies: commonalities and differences.

Katrin Beyer1, Aurelio Ariza.   

Abstract

Synucleinopathies are characterized by the presence of different types of alpha-synuclein (AS)-positive inclusion in the brain. Thus, whereas Lewy bodies are the hallmark of Parkinson disease and dementia with Lewy bodies, glial and neuronal cytoplasmic inclusions are shown by multiple system atrophy. Because the main component of all these inclusions is conformationally modified AS, aggregation of the latter is thought to be a key pathogenic event in these diseases. Although very little information has been available on AS function and aggregation mechanisms until 2 years ago, recent investigations have greatly improved our understanding of the steps involved in the pathogenesis of synucleinopathies. Additionally, important insights into the specific molecular events (e.g. differential posttranslational modifications or isoform expression profiles) underlying each of these conditions have been gained. The present review summarizes our current knowledge of the commonalities and differences shown by protein aggregation mechanisms in the various synucleinopathies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984679     DOI: 10.1097/nen.0b013e3181587d64

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  27 in total

Review 1.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

2.  Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.

Authors:  Abby L Olsen; Mel B Feany
Journal:  Glia       Date:  2019-07-03       Impact factor: 7.452

3.  Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy.

Authors:  Kiren Ubhi; Edward Rockenstein; Michael Mante; Christina Patrick; Anthony Adame; Monica Thukral; Clifford Shults; Eliezer Masliah
Journal:  Neuroreport       Date:  2008-08-27       Impact factor: 1.837

Review 4.  Targeting the chameleon: a focused look at α-synuclein and its roles in neurodegeneration.

Authors:  Blanca A Silva; Leonid Breydo; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2012-09-01       Impact factor: 5.590

5.  Effect of lysosomal and ubiquitin-proteasome system dysfunction on the abnormal aggregation of α-synuclein in PC12 cells.

Authors:  Runqing Wang; Jie Zhao; Jiewen Zhang; Wei Liu; Meiying Zhao; Jiangtao Li; Juan Lv; Yanan Li
Journal:  Exp Ther Med       Date:  2015-04-20       Impact factor: 2.447

Review 6.  Neurodegenerative dementia and parkinsonism.

Authors:  A Gabelle; F Portet; C Berr; J Touchon
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

7.  Screening of Toll-like receptors expression in multiple system atrophy brains.

Authors:  Tomasz Brudek; Kristian Winge; Tina Klitmøller Agander; Bente Pakkenberg
Journal:  Neurochem Res       Date:  2013-03-23       Impact factor: 3.996

8.  Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice.

Authors:  Xing-Long Gu; Cai-Xia Long; Lixin Sun; Chengsong Xie; Xian Lin; Huaibin Cai
Journal:  Mol Brain       Date:  2010-04-21       Impact factor: 4.041

Review 9.  Multiple system atrophy: pathogenic mechanisms and biomarkers.

Authors:  Kurt A Jellinger; Gregor K Wenning
Journal:  J Neural Transm (Vienna)       Date:  2016-04-20       Impact factor: 3.575

10.  Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease.

Authors:  Katrin Beyer; Montserrat Domingo-Sàbat; Jordi Humbert; Cristina Carrato; Isidro Ferrer; Aurelio Ariza
Journal:  Neurogenetics       Date:  2008-03-12       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.